The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: (link sends e-mail)

Study Name on (link is external)
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Study DrugDrug: VX-661 and  VX-770
Type of Study DrugCFTR modulator
Study TitleA Phase 2, Multicenter, Double-Blinded, Placebo Controlled, 3-Part Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/VX-770 Cotherapy in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Study Phase2
Study SponsorVertex

Link on (link is external)

Participating ECFS-CTN sitesGermany: Berlin, Frankfurt, Hannover, Cologne, Munich 
UK: London
Age18 years and older